Latest Sunitinib Stories
Among patients with a high risk of recurrence of a gastrointestinal stromal tumor following surgery for its removal, patients who received imatinib (a drug to treat certain cancers) for 3 years instead of 1 had improved recurrence-free survival and overall survival.
The under-reporting of the possible side effects of heart damage from cancer drugs puts patients at an increased risk for heart failure.
Treatment with three relatively new "targeted" cancer drugs has been linked to a slightly elevated chance of fatal side effects.
- A trick or prank.